Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor

Document Details

Document Type
Pub Defense Publication
Publication Date
Feb 06, 2022
Source ID
10.1080/15384047.2022.2029132

Entities

People

  • Anthony J. Olszanski
  • Dario C Altieri
  • Gary T. Elliott
  • Umar Hayat

Organizations

  • Fox Chase Cancer Center
  • National Cancer Institute
  • United States Department of Defense
  • Wistar Institute